Journal of Laboratory Physicians
Home About us Ahead of print Current issue Back issues Subscribe Instructions Contact Login 
Wide layoutNarrow layoutPrint this page  Email this page Bookmark this page Small font size Default font size Increase font size 
 
HOW I DO IT
Year : 2012  |  Volume : 4  |  Issue : 2  |  Page : 101-111

Rapid Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: Standard Operating Procedure for Non-Commercial Assays: Part 1: Microscopic Observation Drug Susceptibility Assay v2.4.12


1 Department of Laboratory Medicine, Division of Clinical Microbiology, All India Institute of Medical Sciences, New Delhi, India; Culture and Drug Susceptibility Testing Subgroup, New Diagnostic Working Group, STOP TB Partnership, Geneva, Switzerland
2 Department of Laboratory Medicine, Division of Clinical Microbiology, All India Institute of Medical Sciences, New Delhi, India
3 Department of Medical Microbiology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda; Culture and Drug Susceptibility Testing Subgroup, New Diagnostic Working Group, STOP TB Partnership, Geneva, Switzerland
4 Department of Biochemistry and Microbiology, Ghent University, Belgium; Culture and Drug Susceptibility Testing Subgroup, New Diagnostic Working Group, STOP TB Partnership, Geneva, Switzerland
5 Culture and Drug Susceptibility Testing Subgroup, New Diagnostic Working Group, STOP TB Partnership, Geneva, Switzerland

Correspondence Address:
Sarman Singh
Department of Laboratory Medicine, Division of Clinical Microbiology, All India Institute of Medical Sciences, New Delhi, India; Culture and Drug Susceptibility Testing Subgroup, New Diagnostic Working Group, STOP TB Partnership, Geneva, Switzerland

Login to access the Email id

Source of Support: Culture and drug susceptibility testing subgroup, Stop-TB Partnership, WHO & FIND, Geneva, Switzerland, Conflict of Interest: None


DOI: 10.4103/0974-2727.105592

Rights and Permissions

Multidrug-resistant tuberculosis is an increasing public health concern in many parts of the world, especially in low-income countries, where most cases occur. Traditional mycobacteria culture and drug susceptibility testing (DST) is either time-consuming or expensive and for that reason uptake of these technologies has remained limited in many resource-constrained settings. However, several non-commercial culture and DST methods that do not require sophisticated infrastructure and techniques have been developed. One such method is the microscopic observation drug susceptibility assay (MODS). In this method microcolonies that form in the liquid culture medium after specimen inoculation to drug-free and drug-containing micro-wells are detected by visual observation with a simple inverted microscope. The identification and drug susceptibility results can be obtained in 7-15 days. This standard operating procedure document has been developed through the culture and DST subgroup of the STOP TB Partnership, New Diagnostic Working Group. It is intended for laboratories that would want to use or already using this rapid non-commercial method for culture identification and DST of Mycobacterium tuberculosis, notably in resource-constraint settings in Asia and Africa.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2824    
    Printed99    
    Emailed0    
    PDF Downloaded263    
    Comments [Add]    
    Cited by others 2    

Recommend this journal